Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311974 | 0.90 | LMNA (0.63) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4326148 | 0.89 | LMNA (0.64) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4415946 | 0.86 | LMNA (0.61) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4417416 | 0.84 | LMNA (0.59) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4413754 | 0.83 | MEN1 (0.52) | MEN1KMT2A | |
| SCHEMBL4321986 | 0.82 | MEN1 (0.69) | MEN1KMT2AALDH1A1L3MBTL1MAPT | |
| SCHEMBL4423684 | 0.81 | KMT2A (0.70) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL26296804 | 0.80 | SMN1; SMN2 (0.71) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4417155 | 0.79 | SLC6A7 (0.65) | MEN1KMT2AALDH1A1NAMPT | |
| SCHEMBL4417052 | 0.78 | HSD11B1 (0.76) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | LMNA 4354/4885HTT 1727/4885MEN1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.